Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects

References

• Orange JS, Hossny EM, Weiler CR et al.; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117(Suppl. 4), S525–S553 (2006).
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 367(21), 2015–2025 (2012).
   PubMed Web of Science ®Google Scholar
• Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins – a review of the literature. Clin. Rev. Allergy Immunol. 38(2–3), 201–269 (2010).
   PubMed Web of Science ®Google Scholar
• Chérin P, Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs 24(4), 211–223 (2010).
   PubMed Web of Science ®Google Scholar
• Berger M, Pinciaro PJ; Flebogamma 5% Investigators. Safety, efficacy, and pharmacokinetics of Flebogamma 5% (immune globulin intravenous [human]) for replacement therapy in primary immunodeficiency diseases. J. Clin. Immunol. 24(4), 389–396 (2004).
   PubMed Web of Science ®Google Scholar
• Church JA, Leibl H, Stein MR et al.; US-PID-IGIV 10% – Study Group 10. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary immunodeficiency. J. Clin. Immunol. 26(4), 388–395 (2006).
   PubMed Web of Science ®Google Scholar
• Ochs HD, Pinciaro PJ; Octagam Study Group. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J. Clin. Immunol. 24(3), 309–314 (2004).
   PubMed Web of Science ®Google Scholar
• Nezlin R. Interactions between immunoglobulin G molecules. Immunol. Lett. 132(1–2), 1–5 (2010).
   PubMed Web of Science ®Google Scholar
• Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 59(12 Suppl. 6), S28–S32 (2002).
   PubMed Web of Science ®Google Scholar
• Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. l-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals 38(1), 150–157 (2010).
   PubMed Web of Science ®Google Scholar
• Cramer M, Frei R, Sebald A, Mazzoletti P, Maeder W. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with l-proline. Vox Sang. 96(3), 219–225 (2009).
   PubMed Web of Science ®Google Scholar
• Teeling JL, Jansen-Hendriks T, Kuijpers TW et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98(4), 1095–1099 (2001).
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Teeling JL, Verhoeven AJ et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 95(5), 1856–1861 (2000).
   PubMed Web of Science ®Google Scholar
• Jenei B, Lázár G, Bartha K, Medgyesi GA. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). Agents Actions 32(3-4), 333–338 (1991).
   PubMedGoogle Scholar
• Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 43(10), 1460–1480 (2003).
   PubMed Web of Science ®Google Scholar
• WHO. Appropriate use of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. Bull. WHO 60, 43–47 (1982).
   PubMed Web of Science ®Google Scholar
• Apte SP, Ugwu SO. A review and classification of emerging excipients in parenteral medications. Pharmaceut. Technol. 46–60 (2003).
   Google Scholar
• Jorgensen L, Hostrup S, Moeller EH, Grohganz H. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients. Expert Opin. Drug Deliv. 6(11), 1219–1230 (2009).
   PubMed Web of Science ®Google Scholar
• Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185(2), 129–188 (1999).
   PubMed Web of Science ®Google Scholar
• Szenczi A, Kardos J, Medgyesi GA, Závodszky P. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution. Biologicals 34(1), 5–14 (2006).
   PubMed Web of Science ®Google Scholar
• Graumann A, Zawada ET Jr. Case report: acute renal failure after administering intravenous immunoglobulin. Postgrad. Med. 122(2), 142–147 (2010).
   PubMed Web of Science ®Google Scholar
• Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr. Drug Saf. 2(1), 9–18 (2007).
   PubMedGoogle Scholar
• Lin RY, Rodriguez-Baez G, Bhargave GA, Lin H. Intravenous γ-globulin-associated renal impairment reported to the FDA: 2004–2009. Clin. Nephrol. 76(5), 365–372 (2011).
   PubMed Web of Science ®Google Scholar
• Itkin YM, Trujillo TC. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy 25(6), 886–892 (2005).
   PubMed Web of Science ®Google Scholar
• Gürcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun. Rev. 9(8), 553–559 (2010).
   PubMed Web of Science ®Google Scholar
• Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J. Am. Soc. Nephrol. 8(11), 1788–1794 (1997).
   PubMed Web of Science ®Google Scholar
• Ochs HD, Siegel J. Intravenous immunoglobulin products. A comparative review. Pharm. Pract. News (2010).
   Google Scholar
• Bauman LA. Fluid volume monitoring with glucose dilution. Anesthesia Analg. 105(4), 1117 (2007).
   Google Scholar
• Scibilia J, Pastorello EA, Zisa G et al. Maize food allergy: a double-blind placebo-controlled study. Clin. Exp. Allergy 38(12), 1943–1949 (2008).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Renal insufficiency and failure associated with immune globulin intravenous therapy – United States, 1985–1998. MMWR Morb. Mortal. Wkly Rep. 48(24), 518–521 (1999).
   PubMedGoogle Scholar
• Chacko B, John GT, Balakrishnan N, Kirubakaran MG, Jacob CK. Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Ren. Fail. 28(2), 193–195 (2006).
   PubMed Web of Science ®Google Scholar
• Octagam®, prescribing information. Immune globulin intravenous (human) 5%, solvent/detergent treated. Octapharma USA, Inc., Hoboken, NJ, USA (2009).
   Google Scholar
• Gaines A, Pierce LR, Bernhardt PA. Fatal iatrogenic hypoglycemia: falsely elevated blood glucose readings with a point-of-care meter due to a maltose-containing intravenous immune globulin product. FDA, Safety and Availability Bulletin (2009).
   Google Scholar
• Burg MB, Kador PF. Sorbitol, osmoregulation, and the complications of diabetes. J. Clin. Invest. 81(3), 635–640 (1988).
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with d-sorbitol-stabilized, formulation. Ann. Pharmacother. 38(12), 2059–2067 (2004).
   PubMed Web of Science ®Google Scholar
• Vo AA, Cam V, Toyoda M et al. Safety and adverse events profiles of intravenous γ-globulin products used for immunomodulation: a single-center experience. Clin. J. Am. Soc. Nephrol. 1(4), 844–852 (2006).
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr. Pharm. Des. 17(2), 112–120 (2011).
   PubMed Web of Science ®Google Scholar
• Onenli-Mungan N, Yüksel B, Elkay M, Topaloglu AK, Baykal T, Ozer G. Type II hyperprolinemia: a case report. Turk. J. Pediatr. 46(2), 167–169 (2004).
   PubMed Web of Science ®Google Scholar
• Sun A, Wu Y, Pot G et al. IgG stabilization in glycine or l-proline formulated immunoglobulin intravenous 10% (IGIV) solutions: 24-month data to support equally effective stabilization. Presented at: Clinical Immunology Society Annual Meeting: Primary Immune Deficiency North America Conference. Chicago, IL, USA, 18 May 2012.
   Google Scholar
• Hagan JB, Wasserman RL, Baggish JS et al. Safety of l-proline as a stabilizer for immunoglobulin products. Expert Rev. Clin. Immunol. 8(2), 169–178 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang R, Szerlip HM. Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy. South. Med. J. 93(9), 901–904 (2000).
   PubMed Web of Science ®Google Scholar
• Siegel J. IVIG medication safety: a stepwise guide to product selection and use. Pharm. Pract. News 77–84 (2011).
   Google Scholar
• Carimune® NF, prescribing information. Nanofiltered Immune Globulin Intravenous (Human), Lyophilized Preparation. CSL Behring AG, Bern, Switzerland (2010).
   Google Scholar
• Flebogamma® 5% DIF, prescribing information. Immune globulin intravenous (human), 5% liquid preparation. Instituto Grifols, Barcelona, Spain (2012).
   Google Scholar
• Gammagard, prescribing information. Immune globulin intravenous (human), liquid 10%. Baxter Healthcare Corporation, CA, USA (2011).
   Google Scholar
• Gammagard S/D, prescribing information. Immune globulin intravenous (human), solvent detergent treated IgA less than 2.2 µg/mL in a 5% solution. Baxter Healthcare Corporation, CA, USA (2011).
   Google Scholar
• Gammaplex®, prescribing information. Immune globulin injection (human) 5%. Bio Products Laboratory, Hertfordshire, UK (2009).
   Google Scholar
• Gamunex®-C, prescribing information. Immune globulin injection (human) 10%, caprylate/chromatography purified. Talecris Biotherapeutics, Inc., NC, USA (2010).
   Google Scholar
• Hizentra™, prescribing information. Immune globulin subcutaneous (human), 20% liquid. CSL Behring AG, Bern, Switzerland (2011).
   Google Scholar
• Privigen®, prescribing information. Immune globulin intravenous (human), 10% liquid. CSL Behring AG, Bern, Switzerland (2011).
   Google Scholar
• Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus. Med. Rev. 17(4), 241–251 (2003).
   PubMed Web of Science ®Google Scholar
• Yel L. Selective IgA deficiency. J. Clin. Immunol. 30(1), 10–16 (2010).
   PubMed Web of Science ®Google Scholar
• Feldmeyer L, Benden C, Haile SR et al. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm. Venereol. 90(5), 494–497 (2010).
   PubMed Web of Science ®Google Scholar
• Jann S, Bramerio MA, Facchetti D, Sterzi R. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J. Neurol. Neurosurg. Psychiatr. 80(1), 70–73 (2009).
   PubMed Web of Science ®Google Scholar
• Sharma KR, Cross J, Ayyar DR, Martinez-Arizala A, Bradley WG. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch. Neurol. 59(5), 751–757 (2002).
   PubMedGoogle Scholar
• Cocito D, Ciaramitaro P, Isoardo G et al. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J. Neurol. 249(6), 719–722 (2002).
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119(Pt 4), 1067–1077 (1996).
   PubMed Web of Science ®Google Scholar
• Hu CA, Phang JM, Valle D. Proline metabolism in health and disease. Preface. Amino Acids 35(4), 651–652 (2008).
   PubMed Web of Science ®Google Scholar
• Mitsubuchi H, Nakamura K, Matsumoto S, Endo F. Inborn errors of proline metabolism. J. Nutr. 138(10), 2016S–2020S (2008).
   PubMed Web of Science ®Google Scholar
• Botto LD, May K, Fernhoff PM et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112(1 Pt 1), 101–107 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan KE. Chromosome 22q11.2 deletion syndrome: DiGeorge syndrome/velocardiofacial syndrome. Immunol. Allergy Clin. North Am. 28(2), 353–366 (2008).
   PubMed Web of Science ®Google Scholar
• Gothelf D, Feinstein C, Thompson T et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am. J. Psychiatry 164(4), 663–669 (2007).
   PubMed Web of Science ®Google Scholar
• Goodman BK, Rutberg J, Lin WW, Pulver AE, Thomas GH. Hyperprolinaemia in patients with deletion (22)(q11.2) syndrome. J. Inherit. Metab. Dis. 23(8), 847–848 (2000).
   PubMed Web of Science ®Google Scholar
• Vorstman JA, Turetsky BI, Sijmens-Morcus ME et al. Proline affects brain function in 22q11DS children with the low activity COMT 158 allele. Neuropsychopharmacology 34(3), 739–746 (2009).
   PubMed Web of Science ®Google Scholar
• Ferreira AG, Stefanello FM, Cunha AA et al. Role of antioxidants on Na+, K+-ATPase activity and gene expression in cerebral cortex of hyperprolinemic rats. Metab. Brain Dis. 26(2), 141–147 (2011).
   PubMed Web of Science ®Google Scholar
• Bavaresco CS, Streck EL, Netto CA, Wyse AT. Chronic hyperprolinemia provokes a memory deficit in the Morris water maze task. Metab. Brain Dis. 20(1), 73–80 (2005).
   PubMed Web of Science ®Google Scholar
• Delwing D, Bavaresco CS, Wannmacher CM, Wajner M, Dutra-Filho CS, Wyse AT. Proline induces oxidative stress in cerebral cortex of rats. Int. J. Dev. Neurosci. 21(2), 105–110 (2003).
   PubMed Web of Science ®Google Scholar
• Moreira JC, Wannmacher CM, Costa SM, Wajner M. Effect of proline administration on rat behavior in aversive and nonaversive tasks. Pharmacol. Biochem. Behav. 32(4), 885–890 (1989).
   PubMed Web of Science ®Google Scholar
• Raux G, Bumsel E, Hecketsweiler B et al. Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum. Mol. Genet. 16(1), 83–91 (2007).
   PubMed Web of Science ®Google Scholar
• Jacquet H, Raux G, Thibaut F et al. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum. Mol. Genet. 11(19), 2243–2249 (2002).
   PubMed Web of Science ®Google Scholar